Aethlon Medical, Inc.

What they do

Aethlon is developing the Hemopurifier, an investigational immunotherapeutic device that uses a proprietary lectin-based resin to bind and remove enveloped viruses and extracellular vesicles (EVs) from biological fluids. The device is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding targeting mannose-rich surfaces on EVs and viruses. The company's primary focus is a Phase 1 oncology trial in Australia in patients with solid tumors who have stable or progressive disease on anti-PD-1 therapy. Aethlon has also evaluated the Hemopurifier in human studies totaling 173 treatment sessions in 44 patients with viral infections or cancer.

Revenue drivers

• Government contracts and grants — Historically the only reported revenue source; the company recorded $574,245 in revenue in fiscal 2023 (quarter ended 2023-03-31) from government contracts, but reported $0 revenue in fiscal years 2025 and 2026 and states it currently has no research grants or contracts.
• Hemopurifier commercialization — No product revenue to date; the Hemopurifier remains investigational and would require regulatory approval and successful commercialization to generate revenue, which the company states may never occur.
• Future government contract or grant income — The company states future profitability, if any, will require successful commercialization of the Hemopurifier or additional government contract or grant income it may obtain; no such contracts or grants are currently in place.

Recent performance

For the fiscal quarter ended June 30, 2026, Aethlon reported a net loss of $1,547,912, an improvement from a $1,761,858 net loss in the prior-year quarter. Consolidated operating expenses decreased 11.9% to $1,579,202 from $1,792,390, driven by lower professional fees and reduced general and administrative and preclinical research costs. Other income was $31,290, primarily interest income, compared to $30,532 in the prior-year period. Cash and cash equivalents were $4,933,579 as of June 30, 2026, with working capital of $4,574,872. The company reported no revenue in the quarter, consistent with fiscal years 2025 and 2026 when revenue was $0.

Strategy

The company's primary focus is advancing its Phase 1 oncology clinical trial in Australia, which is designed to enroll approximately 9 to 18 participants with solid tumors who have stable or progressive disease on anti-PD-1 monotherapy. As of the latest update, the first participant in the third and final dosing cohort had been treated, and enrollment continues across three Australian sites. Aethlon previously received approval for a similar trial in India but elected not to proceed in order to conserve resources and focus on the Australian trial. The company continues to access capital through its At-the-Market offering program and raised approximately $4.0 million in gross proceeds through a public offering subsequent to quarter-end. A manuscript on extracellular vesicle characteristics in Long COVID patients was accepted for publication in the International Journal of Molecular Sciences.

Risks

• No revenue and recurring losses — The company reported $0 revenue in fiscal years 2025 and 2026, has never been profitable, and expects to continue incurring losses for the foreseeable future.
• Substantial doubt about going concern — The 10-K states there is substantial doubt that cash on hand as of March 31, 2026 will carry the company for 12 months beyond the filing date of the financial statements included in the Annual Report.
• Need for additional capital — The company will likely require additional capital to continue advancing clinical development of the Hemopurifier beyond the next 12 months, and there can be no assurance that financing will be available on acceptable terms or at all.
• Clinical and regulatory uncertainty — The Hemopurifier is an investigational device that has not received marketing approval; the ongoing Phase 1 oncology trial has a safety primary endpoint with exploratory biomarker analyses, and successful commercialization may never occur.

Outlook

Management believes cash and cash equivalents as of June 30, 2026, together with proceeds received from sales under its ATM program subsequent to June 30, 2026, are sufficient to fund planned operations for at least twelve months from the issuance date of the condensed consolidated financial statements. The company expects to continue enrollment in the Phase 1 oncology trial in Australia, having treated the first participant in the third and final dosing cohort. Aethlon states it will likely require additional capital in the future to continue advancing clinical development beyond that period, with timing and amount dependent on clinical progress, regulatory activities, manufacturing requirements, and other operating expenditures.